Last reviewed · How we verify

Dysport® (abobotulinumtoxinA)

Seoul National University Hospital · FDA-approved active Small molecule

Dysport® (abobotulinumtoxinA) is a Botulinum toxin Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm. Also known as: Dysport® (abobotulinumtoxinA)injection, AbobotulinumtoxinA, Clostridium botulinum type toxin A toxin-haemagglutinin complex.

Dysport blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Dysport blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm.

At a glance

Generic nameDysport® (abobotulinumtoxinA)
Also known asDysport® (abobotulinumtoxinA)injection, AbobotulinumtoxinA, Clostridium botulinum type toxin A toxin-haemagglutinin complex
SponsorSeoul National University Hospital
Drug classBotulinum toxin
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology, Dermatology, Aesthetics
PhaseFDA-approved

Mechanism of action

AbobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, leading to flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dysport® (abobotulinumtoxinA)

What is Dysport® (abobotulinumtoxinA)?

Dysport® (abobotulinumtoxinA) is a Botulinum toxin drug developed by Seoul National University Hospital, indicated for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm.

How does Dysport® (abobotulinumtoxinA) work?

Dysport blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is Dysport® (abobotulinumtoxinA) used for?

Dysport® (abobotulinumtoxinA) is indicated for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm, Glabellar lines (dynamic wrinkles), Lateral canthal lines (crow's feet).

Who makes Dysport® (abobotulinumtoxinA)?

Dysport® (abobotulinumtoxinA) is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is Dysport® (abobotulinumtoxinA) also known as anything else?

Dysport® (abobotulinumtoxinA) is also known as Dysport® (abobotulinumtoxinA)injection, AbobotulinumtoxinA, Clostridium botulinum type toxin A toxin-haemagglutinin complex.

What drug class is Dysport® (abobotulinumtoxinA) in?

Dysport® (abobotulinumtoxinA) belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is Dysport® (abobotulinumtoxinA) in?

Dysport® (abobotulinumtoxinA) is FDA-approved (marketed).

What are the side effects of Dysport® (abobotulinumtoxinA)?

Common side effects of Dysport® (abobotulinumtoxinA) include Injection site pain or bruising, Headache, Muscle weakness (localized), Ptosis (eyelid drooping), Dry mouth, Neck pain.

What does Dysport® (abobotulinumtoxinA) target?

Dysport® (abobotulinumtoxinA) targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Botulinum toxin.

Related